Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Avectas

Main focus: Next-generation delivery technology for gene editing

Company stage: Pre-clinical

Diseases: Cancer

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Dublin, Ireland

Website: https://avectas.com/

Partners: ONK Therapeutics

Avectas develops its proprietary SOLUPOREĀ® technology to genetically engineer T cells and natural killer (NK) cells to enable the next generation of gene-modified cell therapies. The company has established a collaboration with ONK Therapeutics, however, it yet has to disclose any proprietary or partnered therapeutic programmes.

Tags

HashtagAvectas

Company: Avectas
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine